82 related articles for article (PubMed ID: 2318551)
21. Effect of vinpocetine on red blood cell deformability in vivo measured by a new centrifugation method.
Hayakawa M
Arzneimittelforschung; 1992 Mar; 42(3):281-3. PubMed ID: 1497684
[TBL] [Abstract][Full Text] [Related]
22. Citalopram: interaction studies with levomepromazine, imipramine, and lithium.
Gram LF; Hansen MG; Sindrup SH; Brøsen K; Poulsen JH; Aaes-Jørgensen T; Overø KF
Ther Drug Monit; 1993 Feb; 15(1):18-24. PubMed ID: 8451775
[TBL] [Abstract][Full Text] [Related]
23. Decreased plasma concentrations of imipramine and desipramine following cholestyramine intake in depressed patients.
Spina E; Avenoso A; Campo GM; Caputi AP; Perucca E
Ther Drug Monit; 1994 Aug; 16(4):432-4. PubMed ID: 7974637
[TBL] [Abstract][Full Text] [Related]
24. Blood pressure and heart rate response of panic disorder patients receiving imipramine in a dose-response treatment paradigm.
de Groot CM; Mavissakalian MR
J Clin Psychopharmacol; 1994 Apr; 14(2):107-10. PubMed ID: 8195450
[TBL] [Abstract][Full Text] [Related]
25. Plasma levels of imipramine and desipramine in man after different routes of administration.
Nagy A; Johansson R
Naunyn Schmiedebergs Arch Pharmacol; 1975; 290(2-3):145-60. PubMed ID: 1102994
[TBL] [Abstract][Full Text] [Related]
26. Vinpocetine inhibits the epileptic cortical activity and auditory alterations induced by pentylenetetrazole in the guinea pig in vivo.
Nekrassov V; Sitges M
Epilepsy Res; 2004 Jun; 60(1):63-71. PubMed ID: 15279871
[TBL] [Abstract][Full Text] [Related]
27. Plasma levels of imipramine and adverse effects in children.
Preskorn SH; Weller EB; Weller RA; Glotzbach E
Am J Psychiatry; 1983 Oct; 140(10):1332-5. PubMed ID: 6624965
[TBL] [Abstract][Full Text] [Related]
28. Imipramine blood levels and clinical outcome.
Rigal JG; Albin HC; Duchier AR; D'Aulnay JM; Fenelon JH; Vincon GA; Demotes-Mainard FM
J Clin Psychopharmacol; 1987 Aug; 7(4):222-9. PubMed ID: 3624505
[TBL] [Abstract][Full Text] [Related]
29. Serum imipramine concentrations lower than plasma values.
Hullett FJ; Levy AB; Tachiki KH
J Clin Psychiatry; 1984 Dec; 45(12):516-8. PubMed ID: 6501238
[TBL] [Abstract][Full Text] [Related]
30. The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study.
Skjelbo E; Gram LF; Brøsen K
Br J Clin Pharmacol; 1993 Mar; 35(3):331-4. PubMed ID: 8471415
[TBL] [Abstract][Full Text] [Related]
31. Effects of combined treatment with imipramine and metyrapone in the forced swimming test in rats. Behavioral and pharmacokinetic studies.
Rogóz Z; Skuza G; Wójcikowski J; Daniel WA
Pol J Pharmacol; 2003; 55(6):993-9. PubMed ID: 14730094
[TBL] [Abstract][Full Text] [Related]
32. Imipramine distribution among red blood cells, plasma and brain tissue.
Fisar Z; Krulik R; Fuksová K; Sikora J
Gen Physiol Biophys; 1996 Feb; 15(1):51-64. PubMed ID: 8902557
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of apovincaminic acid in dogs.
Vereczkey L; Pudleiner P
Pol J Pharmacol Pharm; 1987; 39(2):161-5. PubMed ID: 3432163
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic effects of imipramine are counteracted by its metabolite, desipramine, in patients with generalized anxiety disorder.
McLeod DR; Hoehn-Saric R; Porges SW; Kowalski PA; Clark CM
J Clin Psychopharmacol; 2000 Dec; 20(6):615-21. PubMed ID: 11106132
[TBL] [Abstract][Full Text] [Related]
35. [Membrane and functional effects of vinpocetine and tocopherol in rats with experimental cerebral ischemia].
Vishnevskiĭ AA; Korotkevich IG; Zhaparalieva ChO
Biomed Khim; 2009; 55(5):635-42. PubMed ID: 20017394
[TBL] [Abstract][Full Text] [Related]
36. Omeprazole does not change the oral bioavailability or pharmacokinetics of vinpocetine in rats.
Sozański T; Magdalan J; Trocha M; Szumny A; Merwid-Ląd A; Słupski W; Karaźniewicz-Łada M; Kiełbowicz G; Ksiądzyna D; Szeląg A
Pharmacol Rep; 2011; 63(5):1258-63. PubMed ID: 22180371
[TBL] [Abstract][Full Text] [Related]
37. Nonlinear kinetics of imipramine in low and medium plasma level ranges.
Sindrup SH; Brøsen K; Gram LF
Ther Drug Monit; 1990 Sep; 12(5):445-9. PubMed ID: 2293406
[TBL] [Abstract][Full Text] [Related]
38. Lack of pharmacokinetic interaction between vinpocetine and oxazepam.
Storm G; Oosterhuis B; Sollie FA; Visscher HW; Sommer W; Beitinger H; Jonkman JH
Br J Clin Pharmacol; 1994 Aug; 38(2):143-6. PubMed ID: 7981015
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of vinpocetine and its main metabolite apovincaminic acid before and after the chronic oral administration of vinpocetine to humans.
Miskolczi P; Kozma K; Polgár M; Vereczkey L
Eur J Drug Metab Pharmacokinet; 1990; 15(1):1-5. PubMed ID: 2384112
[TBL] [Abstract][Full Text] [Related]
40. Clinical pharmacokinetics of imipramine and desipramine.
Sallee FR; Pollock BG
Clin Pharmacokinet; 1990 May; 18(5):346-64. PubMed ID: 2185906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
